SCHEMBL4919348

SCHEMBL4919348

CCOC(=O)c1ccc(NC(=O)Nc2nc3ccccc3s2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 13/20 0.66
RAB9A P51151 13/20 0.66
MAPT P10636 7/20 0.66
MEN1 O00255 4/20 0.65
KMT2A Q03164 4/20 0.65
NFKB1 P19838 2/20 0.65
NFKB2 Q00653 2/20 0.65
RELA Q04206 2/20 0.65
GAA P10253 1/20 0.65
SMN1; SMN2 Q16637 10/20 0.65
MAPK1 P28482 2/20 0.61
POLB P06746 2/20 0.60
LMNA P02545 1/20 0.60
NPSR1 Q6W5P4 1/20 0.60
STAT1 P42224 2/20 0.58
USP2 O75604 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
ALDH1A1 P00352 3/20 0.56
KDM4E B2RXH2 2/20 0.56
HTT P42858 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4981777 0.87 RAB9A (0.62) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL4920771 0.85 PTPN1 (0.65) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL4921024 0.85 SMN1; SMN2 (0.72) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL209812 0.84 NPC1 (0.70) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL4918089 0.84 NPC1 (0.76) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL5731223 0.84 TRPV1 (0.57) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL11993580 0.83 NPC1 (0.75) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL2245925 0.83 NPC1 (0.79) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL18824211 0.83 RAB9A (0.64) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL351612 0.83 NPC1 (0.69) NPC1RAB9AMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
EP-1786422-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY Prosidion Limited (GB) 2007-05-23 EP disclosed
WO-2006018662-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY PROSIDION LIMITED (GB) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R NPC1 148/4885RAB9A 3359/4885MAPT 4151/4885
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R NPC1 148/4885RAB9A 3359/4885MAPT 4151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.